Shattuck Labs, Inc. develops monoclonal and bispecific DR3-blocking antibodies for inflammatory and immune-mediated diseases. The company’s news centers on SL-325, a Death Receptor 3 antibody targeting the DR3/TL1A pathway, with emphasis on clinical development in inflammatory bowel disease and related immune-mediated conditions.
Recurring updates also cover quarterly financial results, cash and capital-structure disclosures, investor conference participation, inducement equity awards, and governance matters tied to Shattuck’s Nasdaq-listed common stock.
Shattuck Labs (NASDAQ: STTK) will report its Q3 2022 financial results on November 8, 2022, at 4:30 p.m. ET, during a conference call led by CEO Taylor Schreiber. Experts anticipate insights into the company's innovative bi-functional fusion proteins aimed at treating cancer and autoimmune diseases. Currently, the SL-172154 and SL-279252 programs are in Phase 1 trials, utilizing Shattuck's proprietary ARC® platform. Investors can listen to the live webcast on Shattuck's website.
Shattuck Labs (NASDAQ: STTK) announced it will present a poster on its innovative bispecific Gamma Delta T Cell Engager (GADLEN) platform at the Society for Immunotherapy of Cancer's 37th Annual Meeting from November 8-12, 2022, in Boston. The presentation, titled "Antigen targeted butyrophilin heterodimer-based bispecific engagers induce Vγ9δ2+ T cell-mediated anti-tumor activity," will feature insights from Dr. Suresh de Silva and Dr. Derek Franklin. Shattuck is focused on developing novel biologic therapies for cancer and autoimmune diseases, leveraging its proprietary ARC® platform.
Shattuck Labs (NASDAQ: STTK), a clinical-stage biotechnology company, announced its participation in two investor conferences in September 2022. The first event is Citi's 17th Annual BioPharma Conference on September 8, where CEO Taylor Schreiber will present at 2:40 p.m. ET. The second event is H.C. Wainwright's 24th Annual Global Investment Conference on September 12 at 7:00 a.m. ET. Both presentations will be available via live webcast on the company's website, with replays accessible for up to 90 days.
Shattuck Labs reported its Q2 2022 financial results, noting a net loss of $27.4 million, increasing from $23.6 million in Q2 2021. Cash and equivalents totaled $214.2 million, down from $268.8 million at the end of 2021. The company is advancing its SL-172154 clinical trials, with enrollment expected for a Phase 1B trial in ovarian cancer in Q3 2022, and initial data from these and other trials anticipated in 1H 2023. Shattuck maintains guidance that current cash resources will sustain operations into H2 2024 while progressing on its clinical programs.
Shattuck Labs reported Q1 2022 results with a net loss of $24.5 million, equating to $0.58 per share, a significant increase from a loss of $11.8 million in Q1 2021. The company is advancing its clinical trials, including SL-172154 for platinum-resistant ovarian cancer and acute myeloid leukemia, with initial data expected in H1 2023. R&D expenses rose to $19.2 million, driven by process development and trial-related costs. As of March 31, 2022, cash and equivalents stood at $239.2 million, sufficient to support operations into H2 2024, excluding additional funding.
Shattuck Labs (NASDAQ: STTK) announced promising preclinical data at the 2022 AACR Annual Meeting for its innovative cancer therapies. The SL-9258 (TIGIT-Fc-LIGHT) compound showed enhanced anti-tumor effects, particularly in CPI-resistant tumors. Notably, it modulates immune responses and was well tolerated in non-human primates. The company also highlighted the potential of its GADLEN platform in targeting CD19 and CD20 antigens, showing substantial tumor cell killing in preclinical models. Shattuck aims to nominate its next clinical candidate in 2022.
Shattuck Labs, Inc. (NASDAQ: STTK), a clinical-stage biotechnology firm, will be participating in the 21st Annual Needham Virtual Healthcare Conference from April 11-14, 2022. The presentation, featuring CEO Taylor Schreiber and CFO Andrew Neill, will take place on April 11 at 1:30 p.m. ET. This virtual conference aims to highlight Shattuck's innovative bi-functional fusion proteins designed to treat cancer and autoimmune diseases, with ongoing Phase 1 clinical trials for products like SL-172154 and SL-279252. A live webcast will be available on the company's website.
Shattuck Labs reported promising initial clinical data for its bi-functional fusion proteins SL-172154 and SL-279252 in heavily pretreated cancer patients. The data, presented at the Society for the Immunotherapy of Cancer meeting, highlighted favorable safety profiles, dose-dependent immune activation, and evidence of anti-tumor activity. The company also disclosed a significant increase in collaboration revenue from $1.3 million in Q4 2020 to $30.1 million in Q4 2021. Shattuck's cash position stood at $268.8 million, sufficient to support operations into the second half of 2024.
Shattuck Labs, Inc. (NASDAQ: STTK) announced the acceptance of two posters for presentation at the American Association for Cancer Research (AACR) Annual Meeting, April 8-13, 2022, in New Orleans. The posters will feature preclinical data from their GADLEN™ and ARC® platforms, focusing on cancer treatment advancements. Dr. Anne Lai will present on bispecific gamma delta T cell engagers on April 12, while Dr. George Fromm and Kyung Jin Yoo will discuss LIGHT costimulation with TIGIT blockade on April 13. More details and poster access will be available on their website post-event.
Shattuck Labs, Inc. (NASDAQ: STTK), a clinical-stage biotechnology firm, announced participation in two virtual investor conferences in March 2022. The first conference is the 42nd Annual Cowen Healthcare Conference on March 9, featuring a panel discussion on ovarian cancer, presented by Chief Medical Officer Lini Pandite. The second is Oppenheimer's 32nd Annual Healthcare Conference on March 15, with a corporate presentation by Conor Richardson, Senior Director of Finance. Both presentations will be available via live webcast and archived for 90 days.